更新于：2024-11-04
Tibolone
替勃龙
更新于：2024-11-04
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 (1988-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H28O2 |
InChIKeyWZDGZWOAQTVYBX-XOINTXKNSA-N |
CAS号5630-53-5 |
关联
32
项与 替勃龙 相关的临床试验Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
中国绝经后健康女性受试者空腹/餐后单次口服替勃龙片和利维爱®的单中心、随机、开放、两序列、四周期、完全重复交叉设计的生物等效性试验
A Prospective Randomized Controlled Study of the Effects of Different Therapy Regimens on Menopausal Sleep Disorders
100 项与 替勃龙 相关的临床结果
登录后查看更多信息
100 项与 替勃龙 相关的转化医学
登录后查看更多信息
100 项与 替勃龙 相关的专利（医药）
登录后查看更多信息
1,133
项与 替勃龙 相关的文献（医药）2025-01-01BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Tibolone treatment after traumatic brain injury exerts a sex-specific and Y chromosome-dependent regulation of methylation and demethylation enzymes and estrogen receptors in the cerebral cortex
Article
作者: Lagunas, Natalia ; Ganchala, Danny ; Grassi, Daniela ; Arevalo, Maria-Angeles ; Bautista-Abad, Alvaro ; Garcia-Segura, Luis M. ; Pinto-Benito, Daniel ; Garcia-Segura, Luis M ; Ontiveros, Nebai
2024-12-01MATURITAS
Menopause and endometriosis
Review
作者: Martini, Ellis ; Tedeschi, Sara ; Camnasio, Cristina Angela ; Morteo, Vittoria ; Nappi, Rossella E. ; Tiranini, Lara ; Cucinella, Laura ; Cassani, Chiara ; Nappi, Rossella E
The shift in paradigm from the belief that endometriosis exclusively affects women of reproductive age has brought attention to its manifestation in postmenopausal patients. Despite this emerging awareness, there remains a dearth of information in the literature regarding postmenopausal endometriosis, with uncertainties surrounding its prevalence, clinical significance, optimal management strategies, and prognosis. Clinical manifestations of endometriosis in menopausal patients lack specificity, with pain onset possible at any stage of life. The primary approach for symptomatic postmenopausal endometriosis continues to be surgical excision, serving both diagnostic and therapeutic purposes while mitigating the risk of coexisting malignancies. Managing the disease in postmenopausal women presents challenges due to possible contraindications for menopausal hormone therapy and the elevated risk of recurrence and malignant transformation. However, conclusive data regarding the appropriateness of menopausal hormone therapy in women with endometriosis or a history of the disease are lacking. Current recommendations lean towards prioritizing combined menopausal hormone therapy formulations or tibolone over estrogen-only therapies due to their potentially higher malignancy risk. The possible increased risk of osteoporosis and cardiovascular disease in postmenopausal women with endometriosis is likely linked to a history of surgical menopause at an earlier age, but more research is warranted. This narrative review summarizes the available literature and provides insights into the intricate connection between endometriosis and menopause, shedding light on pathogenesis, symptoms, oncologic risk, diagnosis, and treatment.
2024-10-01AMERICAN JOURNAL OF PSYCHIATRY
Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder
Article
作者: Tiihonen, Jari ; Tanskanen, Antti ; Taipale, Heidi ; Sommer, Iris E. ; Brand, Bodyl A. ; Gangadin, Shiral S.
OBJECTIVE:
Antipsychotic effectiveness in preventing relapse declines around menopausal age in women with schizophrenia or schizoaffective disorder (SSD). It is not known whether systemic menopausal hormone therapy (MHT) can help to prevent psychosis relapse.
METHODS:
A within-subject study design was used to study the effectiveness of MHT in preventing relapse in a Finnish nationwide cohort of women with SSD between 40 and 62 years of age who used MHT during follow-up (1994-2017). Hazard ratios adjusted for age and psychotropic drug use were calculated for psychosis relapse as main outcome and any psychiatric hospitalization as secondary outcome.
RESULTS:
The study population comprised 3,488 women using MHT. Use of MHT was associated with a 16% lower relapse risk (adjusted hazard ratio [aHR]=0.84, 95% CI=0.78-0.90) when compared to non-use. Stratified by age, MHT was associated with decreased relapse risks when used between ages 40-49 (aHR=0.86, 95% CI=0.78-0.95) and ages 50-55 (aHR=0.74, 95% CI=0.66-0.83), but not between ages 56-62 (aHR=1.11, 95% CI=0.91-1.37). Similar effectiveness was found for estrogen alone or combined with fixed or sequential progestogens (aHRs between 0.79 and 0.86), transdermal and oral formulations (aHRs 0.75-0.87), and for most specific formulations (aHRs 0.75-0.85), except tibolone (aHR=1.04, 95% CI=0.75-1.44) and formulations with dydrogesterone (aHR=1.05, 95% CI=0.85-1.30). Similar results were observed with any psychiatric hospitalization as outcome measure.
CONCLUSIONS:
The findings underscore the potential value of MHT in preventing psychosis relapse among women with SSD of menopausal age. These findings translate clinical evidence on the neuroprotective effects of estrogens to real-world settings, encompassing a group of women for whom current antipsychotic treatment options may be insufficient.
5
项与 替勃龙 相关的新闻（医药）2024-08-14
·米内网
临床2期申请上市
100 项与 替勃龙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 绝经期后骨质疏松 | 阿根廷 | - | 2006-02-16 |
| 更年期综合症 | 澳大利亚 | 2000-05-19 | |
| 雌激素缺乏症状 | 中国 | 1990-11-26 | |
| 内分泌系统疾病 | - | - | 1988-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 性功能障碍 | 临床3期 | - | 2004-03-23 | |
| 生理性性功能障碍 | 临床3期 | - | 2004-03-23 | |
| 乳腺癌 | 临床3期 | - | 2002-05-01 | |
| 乳腺癌 | 临床3期 | - | 2002-05-01 | |
| 绝经期综合征 | 临床3期 | - | 2001-10-01 | |
| 骨质疏松症 | 临床3期 | - | 2001-07-01 | |
| 脊柱骨折 | 临床3期 | - | 2001-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 3,148 | 蓋艱獵鬱衊憲壓齋夢觸(選憲窪醖遞衊醖繭簾鑰) = 淵觸築鹹餘蓋糧獵鹹網 蓋壓築鑰淵糧餘憲鹽鬱 (餘糧網願襯願獵壓衊廠 ) 更多 | - | 2011-12-01 | |||
Placebo | 蓋艱獵鬱衊憲壓齋夢觸(選憲窪醖遞衊醖繭簾鑰) = 網膚淵壓鬱餘鏇艱製鹽 蓋壓築鑰淵糧餘憲鹽鬱 (餘糧網願襯願獵壓衊廠 ) 更多 | ||||||
临床3期 | 血管舒缩症 辅助 | 3,148 | 廠鬱糧鏇夢襯淵餘蓋蓋(壓鏇獵齋醖製廠鏇淵積): HR = 1.4 (95% CI, 1.14 ~ 1.7), P-Value = 0.001 | 不佳 | 2009-02-01 | ||
Placebo | |||||||
临床3期 | - | 4,538 | 鑰繭繭構淵衊蓋鬱鑰網(鏇糧願構鑰鏇艱鹽醖鏇): relative hazard = 0.31 (95% CI, 0.1 ~ 0.96), P-Value = 0.04 更多 | - | 2008-08-14 | ||
Placebo | |||||||
临床3期 | - | 102 | 構積鏇鏇鑰鬱選廠夢鹹(衊鏇廠構鹽齋鑰範窪鬱) = 願醖獵夢鏇壓選餘顧鬱 膚壓網網艱憲醖醖齋鑰 (鏇鹹獵簾鹹夢範餘廠夢 ) | 不佳 | 2007-07-15 | ||
Placebo | 構積鏇鏇鑰鬱選廠夢鹹(衊鏇廠構鹽齋鑰範窪鬱) = 壓獵壓淵衊鹽醖艱簾壓 膚壓網網艱憲醖醖齋鑰 (鏇鹹獵簾鹹夢範餘廠夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用